Get the Stockscreener App
2.37
3.04%
0.07
Xbiotech Inc stock is traded at $2.37, with a volume of 10,040.
It is up +3.04% in the last 24 hours and up +4.41% over the past month.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
See More
Previous Close:
$2.30
Open:
$2.31
24h Volume:
10,040
Relative Volume:
0.31
Market Cap:
$71.70M
Revenue:
$300.00K
Net Income/Loss:
$-40.16M
P/E Ratio:
-1.799
EPS:
-1.3174
Net Cash Flow:
$-42.36M
1W Performance:
+3.95%
1M Performance:
+4.41%
6M Performance:
+1.28%
1Y Performance:
-24.76%
1-Day Range:
$2.29
$2.36
1-Week Range:
$2.25
$2.47
52-Week Range:
$2.09
$3.61
Xbiotech Inc Stock (XBIT) Company Profile
Name
Xbiotech Inc
Sector
Industry
Phone
512-386-2900
Address
5217 WINNEBAGO LANE, AUSTIN, TX
Compare XBIT vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIT
Xbiotech Inc
|
2.3518 | 70.12M | 300.00K | -40.16M | -42.36M | -1.3174 |
VRTX
Vertex Pharmaceuticals Inc
|
515.90 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.46 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
992.29 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
213.97 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.63 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-19 | Initiated | Piper Jaffray | Overweight |
| Apr-21-17 | Downgrade | Noble Financial | Buy → Hold |
| Jun-28-16 | Reiterated | Noble Financial | Buy |
Xbiotech Inc Stock (XBIT) Latest News
XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS - MarketBeat
XBiotech: Q2 Earnings Snapshot - marketscreener.com
XBiotech (NASDAQ: XBIT) trims R&D spend yet remains loss-making in Q2 2026 - Stock Titan
XBiotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XBiotech Inc (XBIT) Stock News Today - TradingKey
XBiotech (NASDAQ:XBIT) Share Price Crosses Below 200-Day Moving AverageWhat's Next? - MarketBeat
XBiotech Inc (XBIT) Income Statement - TradingKey
XBiotech Inc (XBIT) Institutional Confidence - TradingKey
XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XBiotech Inc (XBIT) Balance Sheet - TradingKey
XBIT|XBiotech Inc|Price:2.300|Chg%:+0.030 - TradingKey
XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XBiotech Inc (XBIT) Cash Flow - TradingKey
XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIT|XBiotech Inc|Price:2.270| - TradingKey
XBiotech, Inc. Actuals & Estimates (FWB:4XB) - TradingView
XBiotech Inc. Revenue Breakdown – NASDAQ:XBIT - TradingView
XBIT|XBiotech Inc|Price:2.270|Chg%:-0.010 - TradingKey
XBiotech Inc. (XBIT) Slips Slightly, Holds Above Key SupportLiquidity Sweep - dars.gov.et
MSN Money - MSN
XBiotech (XBIT) Holds Steady at $2.29 as Range-Bound Trading ContinuesIPO Entry Watch - dars.gov.et
XBiotech Inc. (XBIT) Slides 2.97% as Shares Approach Key Support at $2.18Pairs Trade - dars.gov.et
XBiotech focuses on antibody pipeline as biotech sector evolves - Ad-hoc-news.de
ETFs Investing in XBiotech, Inc. Stocks - TradingView
XBiotech, Inc. Actuals & Estimates (SWB:4XB) - TradingView
XBiotech Inc. (XBIT) Holds Steady at $2.33 as Key Support and Resistance Levels ConvergeVolume Dry Up - dars.gov.et
XBiotech, Inc. Actuals & Estimates (LS:A14QF1) - TradingView
XBiotech, Inc. Actuals & Estimates (MUN:4XB) - TradingView
Price to earnings forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT) - TradingView
Price to sales forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (DUS:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (BX:4XB) - TradingView
Enterprise value to revenue forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BOATS:XBIT) - TradingView
Price to book forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
Enterprise value to EBIT forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech to commence V-SPINE trial enrolment for vilamakitug - MSN
XBiotech (XBIT) Dips 2.53% as Shares Test Support Near $2.19Motive Wave - dars.gov.et
XBiotech Inc. (XBIT) Nears Key Support After 2.5% DeclineAdvance Decline Volume - dars.gov.et
XBiotech Inc. (XBIT) Declines: Testing Key Support Levels After 2.53% DropHigh Beta Stocks - dars.gov.et
XBiotech Inc (XBIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
XBIT Earnings Overview 2026-06-16Profit Warning Alert - dars.gov.et
XBiotech Receives Authorization for V-SPINE Trial - Intellectia AI
XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondy - AD HOC NEWS
XBiotech (XBIT) Receives FDA Nod for V-SPINE Study - GuruFocus
XBiotech clears FDA review for axial spondyloarthritis study - Investing.com
Xbiotech Inc Stock (XBIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):